Anifrolumab-fnia (Saphnelo) — CPB 0997 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0997 — its anifrolumab-fnia (Saphnelo) coverage policy — effective September 26, 2025. If your practice bills J0491 for Saphnelo infusions, here's what your billing team needs to know before submitting claims.

Aetna updated CPB 0997 governing anifrolumab-fnia (Saphnelo) for commercial medical plan members. This policy controls reimbursement for J0491 (injection, anifrolumab-fnia, 1 mg) alongside infusion administration codes CPT 96365–96368 and chemotherapy administration codes CPT 96413–96417. The update carries real financial exposure for rheumatology and specialty infusion practices — Saphnelo runs over $40,000 per year per patient at standard dosing, and a single documentation gap on medical necessity means a denied claim, not a reduced one.

Quick-Reference Table

Aetna Anifrolumab-fnia (Saphnelo) Coverage Criteria and Medical Necessity Requirements 2025

Aetna's Saphnelo coverage policy under CPB 0997 applies to commercial medical plans only. Medicare patients fall under a separate pathway — check Aetna's Medicare Part B criteria page before billing J0491 for any Medicare Advantage member.

Precertification is required on every Saphnelo case. This is not optional, and it applies to all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax a Statement of Medical Necessity form to (888) 267-3277 before the first infusion. If you skip precertification, you own the denial — there's no retroactive fix for a biologics precert missed on a drug this expensive.

The covered diagnosis codes tied to J0491 are the SLE codes M32.0 through M32.9, plus subacute cutaneous lupus erythematosus (L93.1) and lupus anticoagulant syndrome (D68.62). But coverage is not automatic just because the diagnosis fits. The policy explicitly excludes severe active central nervous system lupus from coverage — M32.0 through M32.9 each carry that carve-out. If your patient's chart documentation reflects CNS lupus, expect a claim denial regardless of which M32 code you submit.

Medical necessity documentation has to reflect the specific lupus presentation Aetna covers under this policy. Your prior authorization request and your claim need to align. Discrepancies between the PA approval and the diagnosis code on the claim are a fast track to a denial — and with Saphnelo, that's not a $200 problem.

Aetna's Site of Care Utilization Management Policy also applies here. This is the piece billing teams miss most often. Before J0491 goes on a claim, confirm that the infusion site meets Aetna's criteria under their drug infusion site-of-care policy. Office-based infusions and hospital outpatient infusions are not automatically interchangeable under this policy. If your practice has been sending patients to one setting and hasn't recently verified it meets Aetna's current site-of-care requirements, check now — before September 26, 2025.

Aetna Saphnelo Exclusions and Non-Covered Indications

The biggest explicit exclusion in this coverage policy is severe active central nervous system lupus. Every SLE code in the CPB — M32.0 through M32.9 — carries the CNS lupus carve-out. This means Aetna will not cover Saphnelo for that presentation, even when the underlying diagnosis code is otherwise on the covered list.

The real issue here is documentation specificity. If a patient's medical record references CNS manifestations, Aetna's medical reviewers will find it. Your clinical documentation should clearly distinguish the lupus presentation being treated. If there's any ambiguity about whether a patient has CNS lupus involvement, loop in your medical director before submitting the PA request.

This policy covers commercial plans only. Using CPB 0997 criteria for Medicare Advantage billing is incorrect. Aetna's Medicare Part B pathway has separate criteria — using the wrong framework is a common source of claim denial on biologics.

Coverage Indications at a Glance

Aetna Anifrolumab-fnia (Saphnelo) Billing Guidelines and Action Items 2025

These are the steps your billing team and your clinical staff need to take before or immediately after September 26, 2025.

If your practice has a high Saphnelo volume or significant lupus patient mix, talk to your compliance officer before September 26, 2025. The CNS exclusion and site-of-care requirements are the two areas most likely to generate denials under this modified policy.

CPT, HCPCS, and ICD-10 Codes for Anifrolumab-fnia (Saphnelo) Under CPB 0997

HCPCS Codes — Covered When Selection Criteria Are Met

CPT Codes — Infusion and Administration (Related to CPB 0997)

These codes pair with J0491 for reimbursement of the infusion encounter. Bill the appropriate administration code based on infusion time and method.

HCPCS Codes — Related Drugs (Corticosteroids, Immunosuppressants)

These codes reflect concomitant medications referenced in the CPB. They appear in the policy because Saphnelo is used in the context of background SLE therapy, which commonly includes these agents.

Key ICD-10-CM Diagnosis Codes